Discussion
cancer
CANCER
Modern dose-finding studies and designs are highly specific to individual clinical settings. For example, clinicians may wish to estimate the MTD more precisely by accommodating a particular shape of the dose-toxicity curve or by incorporating information from multiple groups in adaptive designs, etc. Additionally, implementing a dose-finding design for actual phase I cancer clinical trials involves several practical requirements. For instance, it is conventional to have discrete dose levels while allowing only one dose level increment for each patient or cohort. The current section presents several extensions of the basic modeling framework to accommodate such complexities and requirements, thus making the dose selection schemes more realistic.